Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective StudyReport as inadecuate

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study - Download this document for free, or read online. Document in PDF available to download.


Icotinib hydrochloride is a novel epidermal growth factor receptor EGFR tyrosine kinase inhibitor TKI with preclinical and clinical activity in non-small cell lung cancer NSCLC. This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer NSCLC.


82 consecutive patients treated with icotinib as first n = 24 or second-third line n = 58 treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors RECIST was used to evaluate the tumor responses and the progression-free survival PFS and overall survival OS was evaluated by the Kaplan-Meier method.


Median PFS was 4.0 months 95% CI 2.311–5.689. Median OS was 11.0 months 95% CI 8.537–13.463 in this cohort. Median PFS for first and second-third line were 7.0 months 95% CI 2.151–11.8 and 3.0 months 95% CI 1.042–4.958, respectively. Median OS for first and second-third line were 13.0 months 95% CI 10.305–15.695 and 10.0 months 95% CI 7.295–12.70, respectively. In patients with EGFR mutation n = 19, icotinib significantly reduced the risk of progression HR 0.36, 95% CI 0.18–0.70, p = 0.003 and death HR 0.10, 95% CI 0.02–0.42, p = 0.002 compared with those EGFR status unknown n = 63. The most common adverse events were acne-like rash 39.0% and diarrhea 20.7%.


Icotinib is active in the treatment of patients with NSCLC both in first or second-third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile.

Author: Xiaofeng Chen , Quan Zhu , Yiqian Liu, Ping Liu, Yongmei Yin, Renhua Guo, Kaihua Lu, Yanhong Gu, Lianke Liu, Jinghua Wang, Zhaoxi

Source: http://plos.srce.hr/


Related documents